engleski

FC gamma RIIIA and FC gamma RIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphorna

Antibody dependent cellular cytotoxicity (ADCC), mediated by effector cells via immunoglobulin receptors (Fcγ Rs), is considered an important mechanism of rituximab activity in lymphoma. Fcγ RIIIa 158 V/F polymorphism affects ADCC and is associated with differences in response to rituximab monotherapy in patients with indolent lymphoma. We investigated the association of Fcγ RIIIa and Fcγ RIIa polymorphisms and response to R-CHOP in 58 patients with diffuse large B-cell lymphoma (DLBCL). Fcγ RIIIa and Fcγ RIIa polymorphisms did not influence response, event-free or overall survival. These results suggest that ADCC via Fcγ RIIIa and Fcγ RIIIa is not the major mechanism of activity of the R-CHOP combination in DLBCL.

Fcγ R; single nucleotide polymorphism; rituximab; chemotherapy; diffuse large B-cell lymphoma

nije evidentirano